Houston, TXNCT07190469Now EnrollingIRB Ready

Triple Negative Breast Cancer (TNBC) Clinical Trial in Houston, TX

Access cutting-edge triple negative breast cancer (tnbc) treatment through this clinical trial at a research site in Houston. Study-provided care at no cost to qualified participants.

Sponsored by ProteinQure Inc.

Quick Self-Assessment

See if you qualify for this Houston location

Preparing your pre-screening questions…

Expert Care in Houston

Access triple negative breast cancer (tnbc) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related triple negative breast cancer (tnbc) treatment provided free

Apply for This Houston Location

Check if you qualify for this triple negative breast cancer (tnbc) clinical trial in Houston, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Houston

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Houston site if eligible
  4. 4Begin participation

About This Triple Negative Breast Cancer (TNBC) Study in Houston

The primary purposes of this study are to determine the safety and tolerability of PQ203 in patients with advanced solid tumors including triple negative breast cancer (TNBC), and to determine a recommended Phase 2 dose level for future studies in TNBC.

Sponsor: ProteinQure Inc.

Who Can Participate

Inclusion Criteria

At least 18 years old
Histologically or cytologically documented metastatic or locally advanced solid tumor malignancies having progressed through or being otherwise ineligible to receive approved standard-of-care therapies
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
Documented presence of RECIST v1.1 measurable disease
Adequate organ function confirmed by the following laboratory values obtained within 14 days of the first dose of PQ203: Bone Marrow Function
Absolute neutrophil count (ANC) ≥ 1.5 × 10e9/L
Platelets \> 100 × 10e9/L
Hemoglobin ≥ 9 g/dL Hepatic Function
AST, alanine transaminase ALT or ALP ≤ 2.5 × upper limit of normal (ULN); if liver metastases, then ≤ 5 × ULN
Bilirubin ≤ 1.5 × ULN (\< 2 × ULN if hyperbilirubinemia is due to Gilbert's syndrome)
Serum albumin ≥ 35 g/L (3.5 g/dL) Renal Function
Calculated creatinine clearance of ≥ 60 mL/min by the Cockcroft-Gault equation
Urine protein \< 2+ Cardiac Function • Left ventricular ejection fraction (LVEF) ≥ 50% Other
Understand and voluntarily sign an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)/Research Ethics Board (REB)-approved informed consent form prior to any study-specific evaluation.
PT/PTT or INR \<1.2x upper limit of normal
Non-surgically sterile men and women of child bearing potential must agree to use highly effective methods of contraception for at least 4 months beyond the final dose received.
Toxicity of previous antitumor therapy has returned to Grade ≤1

Exclusion Criteria

Patients with primary central nervous system (CNS) malignancies (Patients with stable brain metastases (≥ 4 weeks after a treatment) not requiring steroids or other treatment will be allowed on study).
Blood transfusion within 14 days of study treatment
Serious comorbid medical conditions such as heart, lung, kidney, liver, and brain disease that, in the opinion of the enrolling investigator, could interfere with study treatment
Subjects with history of severe heart disease
QTc interval using Fridericia's formula (QTcF) \> 470 ms
Estimated or known weight \> 115 kg (253 lbs)
Known/suspected pregnancy and/or lactation
Diastolic blood pressure \< 60 mmHg or \>110 mmHg
Uncontrolled intercurrent illness
Long term care facility resident or prisoner
Any prior receipt of a MMAE-containing drug
Any prior receipt of a SORT1-targeting medication
Participation in another clinical study investigating a drug or medical device or a neuro-interventional or surgical procedure that is not considered as standard care in the 30 days preceding study enrolment
Treatment with any of the following:
Chemotherapy or other systemic anti-cancer therapy ≤14 days or 5 half-lives (whichever is shorter) prior to first dose of study drug except for Nitrosoureas or mitomycins ≤42 days
Major surgery ≤28 days from first dose of study drug
Patients with a history of cerebrovascular accident within 6 months of planned first dose.
Patients with clinically symptomatic ocular toxicities
Patients with history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that require steroids, with current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening
Patients with active Grade \>1 peripheral neuropathy

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Houston?

Yes, this clinical trial (NCT07190469) has an active research site in Houston, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Triple Negative Breast Cancer (TNBC) Treatment Options in Houston, TX

If you're searching for triple negative breast cancer (tnbc) treatment options in Houston, TX, this clinical trial (NCT07190469) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Houston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced triple negative breast cancer (tnbc) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all triple negative breast cancer (tnbc) clinical trials near you to find additional studies recruiting in your area.

More Breast Cancer Trials in Houston, TX

See all breast cancer clinical trials recruiting in Houston — not just this study.

Browse Breast Cancer Trials in Houston →

Browse More Trials by Condition

Breast Cancer TrialsTriple Negative Breast Cancer TrialsAnkylosing Spondylitis TrialsGeographic Atrophy TrialsAll Conditions →

Ready to Join in Houston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Houston, TX